Case Report

Pituitary fossa chondrosarcoma: An unusual cause of a sellar suprasellar mass masquerading as pituitary adenoma

Gautam Dutta, Daljit Singh, Hukum Singh, Arvind Kumar Srivastava, Anita Jagetia, Deepashu Sachdeva

Department of Neuro-Surgery, Govind Ballav Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India

E-mail: *Gautam Dutta - gautambblue@hotmail.com; Daljit Singh - drdaljit@hotmail.com; Hukum Singh - dhruvSingh2008@hotmail.com; Arvind Kumar Srivastava - akorivastava2008@gmail.com; Anita Jagetia - anitajagetia@gmail.com; Deepashu Sachdeva - deepashu3783@yahoo.com; *Corresponding author

Received: 02 December 17  Accepted: 12 February 18  Published: 09 April 18

Abstract

Background: Chondrosarcoma is a mesenchymal malignant tumor composed of tumor cells producing cartilage. It is more commonly found in older age group and usually affects the axial skeleton. Intracranial chondrosarcoma is extremely rare, and chondrosarcoma arising from the sellar region are even rarer with only a few cases described in the literature. We report a case of chondrosarcoma mimicking a sellar suprasellar mass with parasellar extension.

Case Description: A 22-year-old male presented with generalized intermittent headache along with diplopia and diminished visual acuity without any history of sexual dysfunction or galactorrhea. His endocrine tests were within normal limits. Magnetic resonance imaging of the brain revealed a large mass which was apparently arising from the sella with a significant suprasellar and left parasellar component with mild compression over the left optic chiasm and deviation of infundibulum to the right. The patient underwent pterional craniotomy and decompression of the mass. The pathologic diagnosis was chondrosarcoma. The patient received postoperative radiotherapy.

Conclusion: This case demonstrates that chondrosarcoma of the sellar region may mimic clinical, endocrinological, and radiological features of more commonly encountered lesions in this region such as nonfunctioning pituitary tumor, craniopharyngioma, meningioma, or chordoma. We discuss the origin, areas of involvement, management, and long-term prognosis of these rare tumors.

Key Words: Chondrosarcoma, parasellar, sellar, suprasellar

INTRODUCTION

Despite overwhelming variety of lesions occurring in the sellar region, at least 75–80% of all sellar/juxtasellar masses are due to one of the “Big Five:” macroadenoma, meningioma, aneurysm, craniopharyngioma, and astrocytoma. Of them, most are of pituitary origin, only approximately 10% are nonpituitary that includes benign and malignant neoplasms, vascular, granulomatous, and inflammatory lesions. Tumors originating from...
the skull base bone are quite rare, one such tumor, the chondrosarcoma, the most malignant cartilaginous tumor, accounts for 6% of skull base neoplasms and 0.15% of all intracranial tumors.\(^5\) We report a rare case of chondrosarcoma originating from dorsum sellae, which was clinically masquerading the characteristics of craniopharyngioma or pituitary tumor. This case denotes the importance of keeping chondrosarcoma as one of the differential diagnoses of sellar and suprasellar masses.

**CASE REPORT**

A 22-year-old male patient presented with complaints of generalized intermittent headache for past 2 years along with diplopia and diminished visual acuity for the past 3 months without any history of sexual dysfunction or galactorrhea. On physical examination, he was a healthy appearing male with normal male hair pattern and masculinization. Neuro-ophthalmologic examination including perimetry was suggestive of bilateral temporal hemianopia more prominent on the left side, diminution of vision (6/6 right side and 6/18 left side), along with features of early optic atrophy on the left side and left lateral rectus palsy. Basal endocrine investigations revealed normal prolactin (serum PRL 345 mU/L; normal < 360 mU/L), normal thyroid function (total serum T4 10.20 mcg/dL; normal range 3.20–12.6 mcg/dL); serum TSH 1.35 mIU/mL (normal range 0.35–5.30 mIU/mL); serum T3 115.1 ng/dL (normal range 60–181 ng/dL), normal serum cortisol (283 nmol/L; normal range at 0900 h, 200–600 nmol/L). Contrast-enhanced computed tomography (CECT) of the brain revealed an irregular contrast-enhancing calcified lesion at the sellar-suprasellar and left parasellar region with erosion of the posterior and anterior clinoid process and dorsum sellae. Magnetic resonance imaging (MRI) of the brain revealed an irregular contrast-enhancing calcified lesion at the sellar-suprasellar and left parasellar region with erosion of the posterior and anterior clinoid process and dorsum sellae. Magnetic resonance imaging (MRI) of the brain revealed a cartilaginous tumor composed of minimally pleomorphic chondrocytes lying in a cartilaginous matrix with areas of ossification, permeation of bony trabeculae with hyperchromatic nuclei, and inconspicuous nucleoli consistent with well-differentiated chondrosarcoma [Figure 2a and b].

Histology revealed a cartilaginous tumor composed of minimally pleomorphic chondrocytes lying in a cartilaginous matrix with areas of ossification, permeation of bony trabeculae with hyperchromatic nuclei, and inconspicuous nucleoli consistent with well-differentiated chondrosarcoma [Figure 2a and b].

Patient was discharged on postoperative day 10. Postoperative CT brain showed that the tumor was completely removed [Figure 3]. Clinically, the patient showed significant improvement in visual acuity in the left eye (preoperative 6/18; postoperative 6/9); however, bitemporal hemianopia persisted. He was referred for radiotherapy.

---

**Figure 1:** (a) CECT brain suggestive of irregular contrast-enhancing calcified lesion at the sellar-suprasellar and left parasellar regions (b) T2 MRI sequence showing heterogenous signal (c) Significant contrast enhancement of the lesion

**Figure 2:** (a) H and E (100×) shows the junction where the tumor is invading and destroying the intercellular lamellated bone (b) H and E 400×, arrow showing invasion and destruction by chondroid cells. The tumor is low grade and sparsely cellular. Prominent nucleoli and single lacunae having two cells were rarely recognized

**Figure 3:** Postoperative CT brain showing gross total removal of the lesion
DISCUSSION

Chondrosarcomas are malignant tumors of cartilage-forming cells that occur mainly in the axial part of the skeleton. The commonly involved intracranial areas are petrosal bone, occipital bone, clivus, and sphenoid bone. [2,11] These tumors represent less than 5% of skull base tumors with approximately 75% arising in the parasellar region. [13] In a study done by Freda et al. [6] of 911 sellar masses, only 83 were of nonpituitary origin, and of these, 11% were cartilaginous in nature, mainly chordomas. Intracranial chondrosarcoma tends to be even rarer, with only 177 reported in the world literature in a recent review of 15 cases of intracranial chondrosarcoma by Korten et al. [2] Most common presenting complaints tend to be diplopia with impaired eyeball movement (51%) followed by headache (31%), but only 14% were noted for decreased visual function. [2] Our case demonstrates the fact that diminished visual acuity and field cuts as the presenting symptoms of sellar region chondrosarcoma can mimic common clinical diagnosis of sellar mass such as pituitary adenoma.

Radiological examination of such tumors almost always shows bone destruction and variable calcification on CT imaging along with involvement of neural and vascular structures on MRI. [21] Literature is sparse regarding the endocrine function of patients of such tumors; in our case, endocrine function of the patient was normal.

Histologically, chondrosarcoma is classified from grades I to IV according to Evans’s classification system. [11] Several previous studies have reported these tumors to be well differentiated. [1,4] and our case also strengthens this fact. The most common differential for chondrosarcoma is chordoma which can be distinguished by histopathology and immunohistochemistry. Differentiation between these two is important because 5-year survival rate of the former is better. [7,10] On immunohistochemistry, chondrosarcoma cells are negative for pan-cytokeratin markers and epithelial membrane antigens, unlike chordoma cells, which are positive for both. [8,12] While most chondrosarcoma tends to occur in a paramedian position, chordomas tend to be located in the midline. Our case also designates the same.

In 53% of neurosurgically treated patients, recurrence of the tumor was found with a mean interval of 32 months, [2,9] and because the extent of resection and residual tumor volume are both important prognostic indicators, it is frequently necessary to proceed to adjuvant therapy. More promising results have been obtained with the use of proton beam irradiation following surgical resection, though treatment-related visual impairment or pituitary insufficiency developed in 12 of 68 patients in one series. [13] With this adjuvant treatment, 5- and 10-year local control rates of 99% and 98%, respectively, have been achieved. [10]

CONCLUSION

This case demonstrates that chondrosarcoma, a very unusual tumor to arise in the sellar-suprasellar region, can mimic features of the more commonly encountered lesions in this region causing diagnostic dilemmas and resulting in intraoperative surprises. A near-complete resection of the tumor should be the primary goal because this is the most important predictor of outcome, along with regular follow-up to assess recurrence.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Allan CA, Kaltzas G, Evanston J, Geddes J, Lowe DG, Prowman PN, et al. Pituitary chondrosarcoma: An unusual cause of a sellar mass presenting as a pituitary adenoma. J Clin Endocrinol Metab 2001;86:386-91.
2. Korten AG, Ter Berg HJ, Spincemaille GH, van der Laan RT, Van de Vel AM. Intracranial chondrosarcoma: review of the literature and report of 15 cases. J Neurol Neurosurg Psychiatry. 65:88 –92,1998.
3. Austin-Seymour M, Munzenrider J, Goitein M, Verhey L, Urie M, Gentry R, et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 1989;70:13-7.
4. Chung YS, Gwak HS, Jung HH, Park HJ, Paek HS, Kim DG, et al. Intracranial chordomas and chondrosarcomas: The effectiveness of surgery and radiation therapy. J Korean Neuurosurg Soc 2000;29:910-7.
5. Cianfriglia F, Pompili A, Occhipinti E. Intracranial malignant cartilaginous tumours. Report of two cases and review of the literature. Acta Neurochir Wien 45:163–75,1978.
6. Freda PU, Wardlaw SL, Post KD. Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab 1996;81:3455-9.
7. Gay E, Selkhar LN, Rubinstein E, Wright DC, Sen C, Janekia IP, et al. Chondomas and chondrosarcomas of the cranial base: Results and follow-up of 60 patients. Neurosurgery 1995;36:887-96.
8. Ishida T, Dorfman H. Chondroid chordoma versus low-grade chondrosarcoma of the base of the skull: Can immunohistochemistry resolve the controversy? J Neuroonccol 1994;18:199-206.
9. Kveton JF, Brackman DE, Glasscock ME, House WF, Hilselberger WE. Chondrosarcoma of the skull base. Otolaryngol Head Neck Surg 1986;94:23-32.
10. Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE, et al. Chondrosarcoma of the base of the skull: A clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999;23:1370-8.
11. Russell DS, Rubinstein L. Pathology of tumors of the nervous systems. 5th ed. London: Edward Arnold; 1989. pp 809-54.
12. Salisbury JR, Isaacson PG. Distinguishing chordoma from chondrosarcoma by immunohistochemical techniques. J Pathol 1986;148:251-2.
13. Suit HD, Goitein M, Munzenrider J, Verhey L, Davis KR, Koehler A, et al. Definitive radiation therapy for chordoma and chondrosarcoma of the base of skull and cervical spine. J Neurosurg 1982;56:377-85.